Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro

The study titled “Broad-spectrum antiviral activity of two structurally analogous CYP3A inhibitors against pathogenic human coronaviruses in vitro” focuses on the antiviral properties of two drugs, cobicistat and ritonavir, against human coronaviruses, particularly SARS-CoV-2 and its variants. Here’s a detailed summary: Background: Coronaviruses like SARS-CoV, MERS-CoV, and SARS-CoV-2 pose a significant risk of outbreaks. The pandemic highlighted the need for effective antivirals. Cobicistat and ritonavir, both CYP3A inhibitors, have shown antiviral activity against early circulating SARS-CoV-2 strains. The study aims to compare their effects on various SARS-CoV-2 variants and other human coronaviruses​​​​. Antiviral Activity against SARS-CoV-2 Variants: The study analyzed…

Studies Investigate Whether Antivirals Like Paxlovid May Prevent Long COVID

This study, published in JAMA, investigates whether antiviral treatments like Paxlovid (nirmatrelvir combined with ritonavir) and Lagevrio (molnupiravir) might prevent Long COVID. Long COVID is defined by the U.S. government as health issues that continue or develop 4 weeks or more after an initial SARS-CoV-2 infection. Key Highlights: This summary provides an overview of the study’s key findings and implications, crucial for understanding the potential role of antiviral treatments in preventing Long COVID. Read More: https://jamanetwork.com/journals/jama/fullarticle/2813149